15 results about "Inhalation powder" patented technology

The invention relates to preparation of pharmaceutical preparations, in particular to a preparation method of spherical particles of budesonide and formoterol inhalation powder. The preparation method comprises the following steps: respectively preparing the lactose, the formoterol and the budesonide into micronized powder, and dividing the micronized lactose into three parts; performing first spheroidization treatment on the first part of micronized lactose to prepare a spheroidized lactose core; uniformly mixing the second part of micronized lactose, micronized formoterol and micronized budesonide to obtain a budesonide and formoterol mixture; carrying out second spheroidization treatment on the spheroidized lactose core and the budesonide formoterol mixture to prepare a spheroidized intermediate; and carrying out third spheroidization treatment on the spheroidized intermediate and a third part of micronized lactose to obtain spheroidized particles. The spheroidized particles prepared by the method are good in roundness, and the uniformity of the delivery dose of the product is remarkably improved; in addition, the key quality attribute of the product can be improved and kept stable.

This invention discloses a traditional Chinese medicine nasal inhalation powder for facial meridian clearing and nasal closure, and its preparation method. The powder is prepared from the following raw materials in parts by weight: 5-10 parts musk, 12-17 parts angelica dahurica, 15-20 parts peppermint, 7-12 parts black sedge, 12-17 parts pearl, 15-20 parts asarum, and 10-30 parts soapberry. This traditional Chinese medicine nasal inhalation powder and its preparation method for facial meridian clearing and nasal closure exhibit multi-target synergistic effects. The effects of this invention are remarkable. The formula is scientific, with the various herbs working together. Musk and Asarum are the principal herbs, which have a strong effect of opening the orifices, refreshing the mind, dispelling wind and cold. Angelica dahurica and Gleditsia sinensis are the assistant herbs, which dispel wind and dry dampness and open the nasal passages. Zaocys dhumnades dispels wind and unblocks the meridians. Peppermint is cooling and dispersing. Pearl detoxifies and promotes tissue regeneration. Together, they assist the principal and assistant herbs in their effects. This combination can not only quickly relieve facial muscle spasms and numbness, but also improve local microcirculation and promote the recovery of nerve function. Nasal administration is fast-acting and takes effect by utilizing the rich vascular network and olfactory nerve pathway of the nasal mucosa.

The application discloses a compound inhalation powder aerosol and a preparation method thereof. The compound inhalation powder aerosol comprises apremilast or a pharmaceutically acceptable salt thereof and an efficacy enhancing substance, wherein the efficacy enhancing substance is nintedanib or a pharmaceutically acceptable salt thereof; and the amount of the efficacy enhancing substance is 0.1-10 times the amount of the apremilast or the pharmaceutically acceptable salt thereof. In the compound inhalation powder aerosol, the drug exposure of apremilast is greatly improved under the action of nintedanib, and a significant enhancement effect is exhibited. Meanwhile, nintedanib further improves efficacy. The powder aerosol is used for pulmonary inhalation administration, and apremilast or the pharmaceutically acceptable salt thereof and nintedanib or the pharmaceutically acceptable salt thereof are used for treating lung diseases, so that the drugs can be directly delivered to effective sites, the administration dose can be further effectively reduced or the drug utilization rate can be improved, the deposition rate can be improved, and the treatment effect can be greatly improved.

The present application relates to a kind of methods for preparing inhalation powder mist, which includes the step of preparing active mixed particles, wherein the preparation method of the active mixed particles includes the following steps: (1) equilibrating active substance with first additive in environment 1 with temperature of 20-40 ℃ and humidity of RH 55-85% for more than 5 hours; (2) airflow mixing the material equilibrated in step (1) to obtain mixture 1; (3) placing mixture 1 obtained in step (2) into vacuum environment with temperature of 30-130 ℃ for equilibration for more than 0.5 hours. This method requires low operation, can reduce material agglomeration, can reduce the extrusion and friction of carrier to active substance, so as to make the product have better stability.

The application discloses a rafenamine triphenylacetic acid salt and an inhalation powder aerosol thereof. The rafenamine triphenylacetic acid salt can be prepared into the inhalation powder aerosol, has good preparation stability, high deposition proportion at an effective site in the body, good curative effect and low side effect, and provides a new drug selection for the treatment of COPD patients.

Provided are a metformin inhalation powder aerosol for treating idiopathic pulmonary fibrosis and a preparation method thereof, including following steps: pretreating a metformin raw material to obtain fine powder, and passing the obtained fine powder through a screen with a mesh size of 100-1000 microns by an pendular granulator at a rotating speed of 200 revolutions per minute to obtain soft particle clusters; pre-spheronizing clusters at a vibration frequency of 100-300 hertz to obtain particle clusters, and then rolling the particle clusters on a granulating pan and spheronizing to obtain spherical particle clusters.

The invention discloses an inhalation preparation for treating IPF diseases. The inhalation preparation is an aerosol inhalation liquid preparation, an inhalation aerosol, an inhalation powder aerosol or a soft aerosol. The inhalation preparation comprises an active drug, and the active drug is any one of apremilast, ibudilast, roflumilast, crisaborole and defamilast. A preparation process of an inhalation preparation is introduced into a traditional preparation, active ingredients of a traditional oral preparation are easily damaged in digestive tracts, the bioavailability is low, the liver first-pass effect is achieved, the effect is slow, and the inhalation preparation capable of remarkably improving IPF is prepared. Tests prove that the prepared inhalation preparation can effectively improve the bioavailability and improve the clinical use effect.

The present application relates to the technical field of pharmaceutical preparations, in particular to a powder aerosol intermediate composition and a preparation method thereof, a sodium ciprofloxacin inhalation powder aerosol and an application thereof. The raw and auxiliary materials of the intermediate composition include 1-7 wt% of sodium ciprofloxacin, 92-98 wt% of lactose and not more than 1% of magnesium stearate, in terms of mass percentage fraction; the D 50 of the sodium ciprofloxacin is 1-5 microns; the D 50 of the lactose is 100-150 microns. The intermediate composition can be used for preparing the sodium ciprofloxacin inhalation powder aerosol, and can realize efficient delivery of the sodium ciprofloxacin, improve the delivery efficiency of the sodium ciprofloxacin at a target site, and reduce systemic side effects. The sodium ciprofloxacin inhalation powder aerosol can be used for treating mild diseases such as cystic fibrosis, interstitial pneumonia and idiopathic pulmonary fibrosis, and thus expands the indications of the sodium ciprofloxacin.

An inhalation powder containing 24.1 μg of glycopyrronium bromide and 12.7 μg of formoterol fumarate dihydrate per unit dose is disclosed. The powder shows a clear bronchodilatory effect in patients with COPD after twice daily administration. After repeated administration, the lung function of the patients is significantly improved.

The present application relates to a kind of polymyxin B sulfate dry powder, inhalation powder aerosol and preparation method thereof.The polymyxin B sulfate dry powder is prepared by spray drying from the aqueous solution of polymyxin B sulfate and carrier;The carrier is composed of guar gum and L-leucine with a mass ratio of 1-2.5:1;The mass percentage of polymyxin B sulfate and carrier is 45%-65%:35%-55%, and the total amount of polymyxin B sulfate and carrier is 100%;The total concentration of polymyxin B sulfate and carrier in the aqueous solution is 3mg / mL-18mg / mL.The polymyxin B sulfate inhalation powder aerosol prepared from the polymyxin B sulfate dry powder can directly deliver the drug to the lung lesions by local administration, with high lung effective deposition rate, greatly reducing the dosage, and can effectively inhibit the formation of bacterial biofilm.

The invention relates to a suction type dry powder inhalation administration device which comprises an administration tube, an administration tube and a suction tube, the administration tube comprises a tube body, a sliding plunger is arranged in the tube body, a blade is arranged on the side portion of the plunger, and the blade extends out of the tube body through an axial seam formed in the tube wall of the tube body; the dosing mechanism comprises a shell, a suction nozzle is arranged at the top end of the shell, a dosing tube space used for containing a dosing tube is arranged in the shell, a driving mechanism used for being matched with the blade is arranged on one side of the dosing tube space, and the driving mechanism can drive the plunger to move by a set distance each time through the blade; the driving mechanism is matched with an operation part elastically connected to the shell so as to drive the driving mechanism to act; the operation part is matched with the medicine feeding mechanism arranged in the suction nozzle and the medicine feeding pipe space, the operation part can drive the medicine feeding mechanism to act so as to achieve switching between the connection state and the disconnection state of the medicine feeding pipe space and the suction nozzle, and the medicine feeding device overcomes the defects of an existing powder aerosol medicine feeding device.

Disclosed is a nintedanib esylate inhalation powder composed of micronized nintedanib esylate and lactose monohydrate. Further disclosed are a preparation method for the nintedanib esylate inhalation powder and use thereof in the preparation of a drug for treating pulmonary diseases such as pulmonary diseases with fibrosis or lung cancer.

This invention discloses an exosome inhalation powder and its preparation method, comprising the following raw materials: exosome stock solution, lyophilization protectant, exosome lyophilized powder, other pharmaceutical excipients, and antioxidants; wherein, the exosome lyophilized powder is made from the exosome stock solution and the lyophilization protectant as raw materials; this invention relates to the field of medical pharmaceutical technology, and the beneficial effects of this invention are that the inhalation powder of this invention contains exosome components, which can regulate the activity and function of immune cells, enhance or inhibit immune responses, reduce inflammatory damage, and exosomes contain a variety of growth factors and proteins, which help tissue repair and regeneration, promote cell proliferation, migration and angiogenesis, accelerate wound healing and tissue regeneration, treat pulmonary fibrosis, and restore alveolar function.

The invention provides a voriconazole inhalation dry powder inhalation. The voriconazole inhalation dry powder inhalation comprises the following components in parts by weight: 60-80 parts of voriconazole; 20.3-30 parts by weight of a phospholipid emulsifier; 1.4 to 2.5 parts by weight of a divalent cation chloride; 0-11 parts by weight of a crystal inhibitor; and no flow aid is contained. Compared with the prior art, by selecting the specific emulsifier and adopting the divalent cation chloride as the emulsion stabilizer, honeycomb structures and wrinkles are generated on the surfaces of the drug particles, so that the specific surface area is increased, the aerodynamic performance of the particles is better, the particles are easier to deliver to the lung, and the purpose of increasing the effective delivery dosage is achieved; and sugar glidants such as lactose do not need to be added, so that the possibility of layering of active ingredients and inactive ingredients in a pharmaceutical preparation process is avoided, and the stability of a preparation process can be effectively improved.

The application belongs to the technical field of biological medicine, and relates to a medicine preparation, in particular to a capsule type inhalation powder aerosol and a preparation method thereof. The active ingredient of the capsule type inhalation powder aerosol is glycopyrronium bromide, the content of the glycopyrronium bromide in each capsule in terms of glycopyrronium is not higher than 20.0 mu g, and the FPF in the air dynamic characteristics is 50.0-75.0%. The capsule type inhalation powder aerosol provided by the application can significantly improve the drug safety on the premise of ensuring the drug efficacy.